<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01694459</url>
  </required_header>
  <id_info>
    <org_study_id>596-2012-D</org_study_id>
    <nct_id>NCT01694459</nct_id>
  </id_info>
  <brief_title>DEDICA (Dose of HEparin During Coronary Angioplasty) Trial</brief_title>
  <acronym>DEDICA</acronym>
  <official_title>Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Filippo Neri General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Filippo Neri General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International guidelines support the use of a full-dose heparin (anticoagulants) during
      coronary intervention. However, a lower dose of heparin may be adequate, thanks to advances
      in angioplasty techniques and the widespread use of pretreatment with two antiplatelet
      agents.

      Thus the investigators designed a study comparing safety and efficacy of standard dose
      heparin (100 UI/Kg) versus low-dose (50 UI/Kg) in patients undergoing coronary angioplasty
      who are on aspirin and clopidogrel at the time of the procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients undergoing coronary angioplasty will be randomised to standard vs. low-dose
           heparin. the study will include &quot;all-comers&quot; (patients with either stable angina or
           acute coronary syndromes); only patients with ST-elevation myocardial infarction will be
           excluded.

        -  An ACT (activated clotting time) will be performed after the initial bolus of heparin:
           for the standard dose group the target ACT will be &gt; 300 sec. (as recommended by
           guidelines) while for the low-dose the target ACT will be &gt; 180 sec.

      Aim of the study is to show equivalence in ischemic events between the two doses of heparin,
      in order to confirm the safety of lower dose of heparin in contemporary coronary
      interventions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE + stent thrombosis + major bleeding (TIMI definition)</measure>
    <time_frame>30 days</time_frame>
    <description>MACE (death, myocardial infarction, target vessel revascularization) + stent thrombosis + major bleeding (TIMI definition)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>30 days</time_frame>
    <description>MACE = death, myocardial infarction, target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding according to TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>Stent thrombosis (definite or probable according to ARC criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CK-MB increase</measure>
    <time_frame>30 days</time_frame>
    <description>Any CK MB increase &gt;3 times upper limit of normal or &gt;50% baseline levels (if baseline levels already &gt;then upper limit of normal)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding according to STEEPLE criteria</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stable Angina</condition>
  <condition>Angina, Unstable</condition>
  <condition>Non-ST Elevation (NSTEMI) Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Standard dose heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) &gt; 300 sec. during the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus of 50 UI/Kg heparin with a target ACT during the procedure of &gt;200 sec.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose heparin</intervention_name>
    <description>Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions</description>
    <arm_group_label>Low-dose heparin</arm_group_label>
    <other_name>50 UI/Kg bolus heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose heparin</intervention_name>
    <description>Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.</description>
    <arm_group_label>Standard dose heparin</arm_group_label>
    <other_name>100 Ui/Kg bolus heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable angina, unstable angina or Non-ST elevation myocardial infarction undergoing
             coronary angioplasty.

          -  Mandatory pretreatment with aspirin and clopidogrel

        Exclusion Criteria:

          -  ST elevation myocardial infarction

          -  Coronary interventions with rotational atherectomy

          -  Coronary interventions on chronic total occlusions (CTO)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Pasceri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Filippo Neri Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Pelliccia, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Roma La Sapienza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincenzo Pasceri, MD</last_name>
    <phone>+39063306</phone>
    <phone_ext>2504</phone_ext>
    <email>vpasceri@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+393483392006</phone>
    <email>md4151@mclink.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rome La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Pelliccia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Gaudio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Filippo Neri General Hospital</investigator_affiliation>
    <investigator_full_name>Vincenzo Pasceri</investigator_full_name>
    <investigator_title>Attending Cardiologist</investigator_title>
  </responsible_party>
  <keyword>angioplasty</keyword>
  <keyword>heparin</keyword>
  <keyword>trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

